Cara Therapeutics - Outbreak or Selloff?

Cara Therapeutics is back on the strong resistance line that has been tested 4 times. Only once, in June 2017, was this briefly broken after FDA breakthrough therapy designation.
CR845 reduces itching in patients with chronic liver insufficiency. This brought in June 2018 3 large pharmaceutical companies on the plan, who wanted to market this product against once and milestone payments.

Outlook:
To confirm the breakout, a week-end above the blue resistance line is necessary. Following this, a retest of this resistance would be ideal to confirm this as a support zone.

If share price can not establish a weekly close above, is to expect a subsequent sale.

greeting
Stefan Bode